Gilead Sciences has revealed a range of positive data from its HIV research pipeline, showcasing its innovative treatment strategies. The revelations, made at the 31st Conference on Retroviruses and Opportunistic Infections (CROI), revolve around lenacapavir, a first-in-class capsid inhibitor, and bictegravir, an integrase strand transfer inhibitor. ARTISTRY-1, a Phase 2/3 study, compared an investigational once-daily combo of bictegravir and lenacapavir versus current therapies in virologically suppressed HIV patients on complex regimens. Results showed both patient groups had robust virologic suppression at six months, with consistently low viral loads throughout the study. In another study, lenacapavir was combined with broadly neutralizing antibodies, affirming the potential role of long-acting agents in future antiretroviral therapy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
